Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310413 | 0.93 | CTSC (0.35) | DRD2DRD3CTSCHTR1ADRD4 | |
| SCHEMBL24310455 | 0.89 | DRD2 (0.31) | DRD2DRD3CTSCPTK2 | |
| SCHEMBL24309539 | 0.88 | TACR1 (0.32) | DRD2DRD3CTSC | |
| SCHEMBL24309527 | 0.85 | DRD2 (0.39) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL29566783 | 0.83 | HTR6 (0.34) | DRD2DRD3CTSCHTR1ADRD4 | |
| SCHEMBL24309538 | 0.83 | HTR6 (0.34) | DRD2DRD3CTSCHTR1ADRD4 | |
| SCHEMBL24310404 | 0.83 | TACR1 (0.33) | DRD2DRD3CTSCTIPARP | |
| SCHEMBL24310784 | 0.83 | MAP3K7 (0.32) | — | |
| SCHEMBL24309803 | 0.80 | DRD3 (0.37) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL24310558 | 0.80 | IGF1R (0.31) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |